Roche Cobas Malaria Test Gets FDA Approval For Donor Screening

Blood product manufacturers and transfusion center QA leads now have a FDA-cleared nucleic acid test (NAT) for Plasmodium screening in donor blood, a development that signals expanding biologics screening obligations under 21 CFR Part 610. Roche Molecular Systems received approval for the cobas Malaria test on March 19, 2024, under STN 125808, extending the cobas 6800/8800 platform's screening portfolio into transfusion-transmitted malaria risk.

The assay detects DNA and RNA from five Plasmodium species, P. falciparum, P. malariae, P. vivax, P. ovale, and P. knowlesi, in whole blood from individual donors of whole blood, blood components, and other living donors. Critically, the indication extends to organ and tissue donors where samples are collected while the donor's heart is still beating, broadening the test's relevance beyond blood banks to transplant procurement organizations and hospital-based organ donor programs.

For QA directors managing donor screening SOPs, the individual-sample testing requirement is operationally significant. Unlike pooled NAT strategies used in some infectious disease screening workflows, cobas Malaria mandates unit-by-unit testing, which carries direct implications for throughput planning, reagent inventory management, and batch release timelines on high-volume platforms. Facilities already running cobas 6800/8800 systems for HIV, HCV, or HBV NAT will need to assess protocol integration and any required revalidation under their existing process validation frameworks.

The approval letter and Summary Basis for Regulatory Action, both dated March 2024, are publicly available via FDA's biologics database and provide the evidentiary basis for facilities updating their donor screening quality systems. Regulatory affairs leads preparing submissions or responding to FDA biologics inspections should note the defined exclusions: the test is not indicated for cord blood or cadaveric specimens, boundaries that will need explicit documentation in any site-specific screening SOPs to avoid scope creep during audits.

The cobas Malaria clearance arrives as FDA continues to evaluate transfusion-transmitted infection risk from emerging and re-emerging vector-borne pathogens, and blood establishments should anticipate that guidance on malaria donor screening deferral policies may be revisited in parallel with this new testing capability.

Source: FDA Vaccines, Blood and Biologics / Approved Blood Products database, September 10, 2026.